Published in Cardiovascular Business Week, August 19th, 2008
"GGF2 represents a potentially novel and exciting therapeutic approach to cardiac damage and heart...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.